Skip to main content

Table 1 Demographic and clinical characteristics of the study population (n = 515)

From: A prospective study of hepatic safety of statins used in very elderly patients

VariablesPercent (N)
Age (years)83.8 ± 3.4
 80  8563.5% (327)
 85  9029.5% (152)
  ≥ 907% (36)
Sex
 Male79.6% (410)
 Female20.4% (105)
Hepatitis B
 Yes4.3% (22)
 No95.7% (493)
Fatty liver
 Yes9.1% (47)
 No90.9% (468)
Biliary calculus 
 Yes17.1% (88)
 No82.9% (427)
Other diseasesa
  ≤ 26% (31)
 3  541.2% (212)
  ≥ 552.8% (272)
Other drugsb
  < 519.2% (99)
 5  1071.5% (368)
  ≥ 109.3% (48)
Drinking habitsc
 No drinking95.3% (491)
 Mild to moderate2.7% (14)
 Heavy1.9% (10)
Statin variety
 Simvastatin19.1% (98)
 Fluvastatin22.5% (116)
 Pravastatin15.5% (80)
 Rosuvastatin16.5% (85)
 Atorvastatin26.4% (136)
Statin dose
 Low13.6% (70)
 Standard86.4% (445)
  1. aIncluding hypertension, diabetes, cerebral infarction, atrial fibrillation, chronic bronchitis, chronic obstructive pulmonary disease, chronic gastritis, osteoporosis, benign prostatic hyperplasia, and biliary calculus
  2. bIncluding antihypertensive agents, antidiabetic agents, clopidogrel, aspirin, beta-blockers, isosorbide mononitrate, trimetazidine, citicoline, cilostazol, warfarin, digoxin, ambroxol, aminophylline, rebamipide, rabeprazole, calcitriol, calcium carbonate, oral bisphosphonates, finasteride, tamsulosin, and digestive enzymes
  3. cNo drinking: not drinking in a previous year; light drinkers: current use of 3 drinks per week; moderate drinkers: current use of 3 to 7 drinks per week for women, and 3 to 14 drinks per week for men; heavy drinkers: current use of more than 7 drinks per week for women and 14 drinks per week for men